Strattera 25 mg/1 (Atomoxetine hydrochloride CAPSULE) 25 mg/1

Strattera 25 mg capsules contain atomoxetine hydrochloride, a non-stimulant medication used for ADHD management. This oral capsule is designed to help improve focus and reduce impulsivity.

Strength

25 mg/1

Pack Size

30 CAPSULE in 1 BOTTLE (0002-3228-30)

Manufacturer / TM Owner

Eli Lilly and Company

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Strattera 25 mg capsules are primarily used for the treatment of attention deficit hyperactivity disorder (ADHD). Atomoxetine hydrochloride works by affecting certain chemicals in the brain that contribute to hyperactivity and impulse control. This medication is often prescribed to help manage symptoms such as inattention, hyperactivity, and impulsiveness.

Side Effects

Common effects of Strattera 25 mg capsules may include decreased appetite, nausea, and stomach pain. Some users may also experience dizziness, fatigue, or mood changes. These effects can vary from person to person and may subside as the body adjusts to the medication.

Precautions & Warnings

Strattera 25 mg capsules should be handled with care. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. This medication should be stored at room temperature, away from moisture and heat. Always consult a healthcare provider before starting or stopping any medication.

Avoid Interactions

Strattera 25 mg capsules may interact with certain medications, including MAO inhibitors, antidepressants, and other drugs that affect brain chemicals. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol consumption should also be discussed with a healthcare professional.

References

Frequently Asked Questions

Strattera is primarily used for the management of attention deficit hyperactivity disorder (ADHD).

Strattera 25 mg capsules are taken orally, typically once or twice a day as directed by a healthcare provider.

Common side effects may include decreased appetite, nausea, stomach pain, dizziness, and fatigue.

Strattera may interact with certain medications, so it is important to consult a healthcare provider before combining it with other drugs.

Long-term use of Strattera should be monitored by a healthcare provider to ensure safety and effectiveness.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.